Clinical evaluation of the plasma levels of hTERT and EGFR expression as markers for early detection of non-small cell lung cancer Source: Annual Congress 2009 - Basic science and lung cancer Year: 2009
The clinical significance of plasma DNA quantification in NSCLC Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011
The prognostic value of altered pRb and p53 protein expression in non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 363s Year: 2003
Clinicopathological significance and prognostic importance of circulating plasma DNA expression in advanced non-small cell lung cancer and its efficacy as a diagnostic tool Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012
Can high levels of serum tumor markers be useful in predicting the histologic type of lung cancer? Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004
Clinical significance of serum cathepsin K level during chemotherapy of lung cancer. Can we use it as a marker of small cell lung cancer? Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008
Prognostic value of p21 protein expression in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004
Clinical significance of serum osteopontin levels in lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
Clinical significance of serum survivin, MGB-1 and Pref-1 levels during chemotherapy of lung cancer Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009
Studies on clinical significance and relationship with PI and gene protein expression of p16, Rb and Cyclin-D1 in lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002
The diagnostic value of serum tumor markers in newly diagnosed lung cancer patients Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017
The clinical significance of soluble E-cadherin in lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 769s Year: 2006
p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001
Cancer-associated oncogenic BARD1 isoforms: From biomarker expression studies to development of a blood test for early detection of lung cancer Source: Annual Congress 2012 - Early detection of lung cancer Year: 2012
Evaluation of serum tumour markers in the lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 268s Year: 2002
Free plasmatic circulating DNA as prognostic and diagnostic lung cancer biomarker Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases Year: 2008
The association of p53 and p21 expression with clinicopathological parameters and prognosis in non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010
Early detection of lung cancer: role of biomarkers Source: Eur Respir J 2003; 21: 36S-44S Year: 2003
CEA levels in the serum and induced sputum of lung cancer patients Source: Eur Respir J 2005; 26: Suppl. 49, 324s Year: 2005
Distribution of BCL-2 gene expression and its prognostic value in non-small cell pulmonary cancer Source: Eur Respir J 2002; 20: Suppl. 38, 72s Year: 2002